argenx SE (NASDAQ:ARGX) Receives Average Recommendation of “Moderate Buy” from Brokerages

argenx SE (NASDAQ:ARGX) has been given an average recommendation of “Moderate Buy” by the twenty-one brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation, fourteen have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $530.74.

ARGX has been the subject of several analyst reports. Robert W. Baird decreased their price objective on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Scotiabank increased their target price on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 26th. Wolfe Research started coverage on shares of argenx in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. Wells Fargo & Company increased their target price on shares of argenx from $472.00 to $478.00 and gave the company an “overweight” rating in a research report on Tuesday, February 20th. Finally, JMP Securities reissued a “market outperform” rating and set a $471.00 target price on shares of argenx in a research report on Friday, March 22nd.

argenx Price Performance

ARGX opened at $370.68 on Wednesday. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $550.76. The firm has a market capitalization of $21.98 billion, a PE ratio of -72.12 and a beta of 0.65. The company’s 50-day moving average is $389.50 and its 200 day moving average is $422.65.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The firm had revenue of $417.84 million during the quarter, compared to analysts’ expectations of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same quarter last year, the business posted ($0.70) EPS. As a group, analysts expect that argenx will post -2 EPS for the current year.

Hedge Funds Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in ARGX. KB Financial Partners LLC raised its position in argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the period. ADAR1 Capital Management LLC purchased a new position in argenx in the 4th quarter worth $27,000. Parkside Financial Bank & Trust purchased a new position in argenx in the 3rd quarter worth $28,000. GAMMA Investing LLC raised its position in argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after purchasing an additional 63 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in argenx in the 4th quarter worth $38,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.